Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan, China

Li, Chaowei; Chen, Qingshi; Wang, Jianwen; Lin, Huasong; Lin, Ya-Lan; Lin, Jiawei; Peng, Fangzhan; Chen, Jiangmu; Yang, Zhimin

doi:10.18632/aging.103632

Cited by 15 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous study elucidated the high mortality rate among CLD patient who they are Covid-19 infected. 23 , 24 Our findings also highlighted the high mortality rate and the long period of hospitalisation among cancer patients. The nature of cancer and the antineoplastic agents compromise the immune system.…”

Section: Discussionsupporting

confidence: 58%

Predictors of Length of Hospital Stay, Mortality, and Outcomes Among Hospitalised COVID-19 Patients in Saudi Arabia: A Cross-Sectional Study

Alwafi¹,

Naser²,

Qanash³

et al. 2021

JMDH

View full text Add to dashboard Cite

Background COVID-19 pandemic is a major strain on health and economic systems, with rapidly increasing demand for in patients’ facilities. Disease diagnosis and estimating patients at higher risk is important for the optimal management during the pandemic. This study aimed to identify the predictors of mortality and length of hospital stay in COVID-19 patients. Methods A retrospective cross-sectional study was conducted between March 2020 and August 2020 at Al-Noor Specialist Hospital in Mecca, Saudi Arabia. All patients who were admitted and had a confirmed COVID-19 diagnosis by a real-time polymerase chain reaction (PCR) were included in the study. Descriptive statistics were used to describe patients’ demographic characteristics, laboratory findings, and clinical outcomes. Multiple logistic/linear regression analysis was used to identify predictors of death and length of stay at the hospital. Results A total of 706 patients were hospitalised for COVID-19. The mean age was 48.0 years (SD: 15.6 years). More than half of the patients (68.5%; n= 292) were males. The median duration of stay at the hospital was 6.0 days (IQR: 300–10:00). The prevalence rate of venous thromboembolism (VTE) among the patients was 3.0% (n= 21). In the multivariate logistic regression analysis, age (AOR: 1.05; 1.02–1.09), patients with end-stage renal disease (AOR: 6.44; 2.20–18.87), low Oxygen saturation SPO2 (AOR: 9.92; 4.19–23.50), D.dimer >0.5 (AOR: 13.31; 5.45–32.49), ESR>10 mm/h (AOR: 4.08; 1.72–9.68), Ferritin>400mcg/L (AOR: 18.55; 6.89–49.96), and Procalcitonin>0.5ug/L (AOR: 8.23; 1.81– 37.40) were associated with a higher risk of death among patients with COVID-19. Patients with VTE (AOR: 12.86; 3.07– 53.92) were at higher risk of death due to COVID-19. Conclusion Hospitalised COVID-19 patients have multiple negative consequences in terms of their laboratory findings, signs and symptoms. Age and end-stage renal diseases have a significant impact on the mortality rate and the length of hospital stay among COVID-19 patients.

show abstract

Section: Discussionsupporting

confidence: 58%

Predictors of Length of Hospital Stay, Mortality, and Outcomes Among Hospitalised COVID-19 Patients in Saudi Arabia: A Cross-Sectional Study

Alwafi¹,

Naser²,

Qanash³

et al. 2021

JMDH

View full text Add to dashboard Cite

show abstract

“…The risk of death in COVID‐19 patients with chronic liver disorders was compared with that in ones without the CLD in 15 studies 19,26,28–40,42 . In all of these studies, the mortality rate in patients with COVID‐19, and the CLD was higher than that in patients with COVID‐19, and without the CLD 19,26,28,30,32–34,36–40 . The cumulative RR after combining these studies was 1.52 (CI 95%: 1.46–1.57; I 2 : 86.14%) (Figure 2).…”

Section: Resultsmentioning

confidence: 99%

The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies

Afraie

Mohammadzedeh

Azami

et al. 2022

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction:The aim of this review was to combine the results of published cohort studies to determine the exact association between chronic liver disorders, and the severe form of COVID-19, and its associated complications. Methods: This meta-analysis employed a keyword search (COVID-19 and chronic liver disorders) using PubMed (Medline), Scopus, Web of Sciences, and Embase (Elsevier). All articles related from January 2019 to May 2022 were reviewed. The STATA software was used for analysis. Results: The risk of death in COVID-19 patients with chronic liver disorders was higher than in ones without the chronic liver disease (RR: 1.52; CI 95%: 1.46-1.57; I 2 : 86.14%). Also, the risk of acute respiratory distress syndrome (ARDS) and hospitalization in COVID-19 patients with chronic liver disorders was higher than in ones without the chronic liver disease ([RR: 1.65; CI 95%: 1.09-2.50; I 2 : 0.00%] and [RR: 1.39; CI 95%: 1.23-1.58; I 2 : 0.20%]). Also, the meta-analysis showed cough, headache, myalgia, nausea, diarrhea, and fatigue

show abstract

“…In total, 26 studies reported on the mortality outcome among CLD and non-CLD patients (8,(10)(11)(12)15,19,20,22,(24)(25)(26)29,30,33,35,38,39,41,(44)(45)(46)(47)(48)(49)(50)(51). The pooled OR was 2.35 (95% CI, 1.84-3.00; I 2 = 96.26%; 95% PI, 0.76-7.18) (Figure 3), indicating that COVID-19 patients with CLD had 2.35 times higher odds of dying as patients without CLD.…”

Section: Mortalitymentioning

confidence: 99%

COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis

et al. 2022

View full text Add to dashboard Cite

Introduction Pre-existing comorbid conditions in COVID-19 patients are risk factors for developing severe disease and death. We aimed to determine the association of chronic liver disease (CLD), a comorbid condition, with severity of disease and death among COVID-19 patients. Methods We searched for studies reporting COVID-19 outcomes among CLD and non-CLD patients in databases including Medline, EMBASE, ScienceDirect, Google Scholar, and Cochrane Library from inception of the pandemic until February 2022. Risk of bias assessment was conducted by using the Newcastle-Ottawa Scale for assessing the quality of nonrandomized studies in meta-analyses. We conducted a meta-analysis with a random-effects model and reported pooled odds ratios (ORs) with 95% CIs. Results We included 40 studies with 908,032 participants. Most studies were conducted in China and the US. COVID-19 patients with CLD had significantly higher odds of having a severe form of COVID-19 (pooled OR = 2.44; 95% CI, 1.89–3.16) and death (pooled OR = 2.35; 95% CI, 1.85–3.00) when compared with COVID-19 patients without CLD. Conclusion The presence of CLD is significantly related to adverse clinical outcomes among COVID-19 patients in terms of severity and mortality. Clinicians should develop a comprehensive intervention plan to manage these high-risk patients and reduce COVID-19–related deaths.

show abstract

Clinical characteristics of chronic liver disease with coronavirus disease 2019 (COVID-19): a cohort study in Wuhan, China

Cited by 15 publications

References 19 publications

Predictors of Length of Hospital Stay, Mortality, and Outcomes Among Hospitalised COVID-19 Patients in Saudi Arabia: A Cross-Sectional Study

Predictors of Length of Hospital Stay, Mortality, and Outcomes Among Hospitalised COVID-19 Patients in Saudi Arabia: A Cross-Sectional Study

The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies

COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About